WO2004043964A2 - Process for the preparation of quaternary n-alkyl morphinan alkaloid salts - Google Patents
Process for the preparation of quaternary n-alkyl morphinan alkaloid salts Download PDFInfo
- Publication number
- WO2004043964A2 WO2004043964A2 PCT/US2003/035463 US0335463W WO2004043964A2 WO 2004043964 A2 WO2004043964 A2 WO 2004043964A2 US 0335463 W US0335463 W US 0335463W WO 2004043964 A2 WO2004043964 A2 WO 2004043964A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- methyl
- solvent
- aprotic dipolar
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Definitions
- the present invention generally relates to a process for the synthesis and/or recovery of quaternary N-alkyl salts of morphinan alkaloids.
- N-methyl quaternary derivatives of morphinan alkaloids such as naltrexone ((5 ⁇ )-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6- one sometimes referred to as N-cyclopropylmethyl-noroxymorphone) and naloxone ((5 ⁇ )-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one sometimes referred to as N-allyl-noroxymorphone) have useful pharmacological properties as potent antagonists of the mu receptor.
- naltrexone ((5 ⁇ )-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6- one sometimes referred to as N-cyclopropylmethyl-noroxymorphone)
- naloxone ((5 ⁇ )-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one sometimes
- peripheral receptors primarily located in the gastrointestinal tract, act as antagonists and effectively mitigate some of the undesirable side effects of opiate therapy such as constipation and nausea. Because of their ionic charge, however, they do not traverse the blood brain barrier into the central nervous system; hence, the central activity of opiates responsible for pain relief is not blocked in the presence of these quaternary derivatives.
- Goldberg, et al. generally describe the preparation of quaternary derivatives of certain morphinan alkaloids by quaternizing a tertiary N-substituted morphinan alkaloid with a methylating agent such as methyl bromide, methyl iodide or dimethylsulfate. Goldberg et al.
- the methylating agent itself may be used as the solvent or, alternatively, another solvent medium such as methanol, ethanol, or other alcohols, methylene chloride, chloroform, tetrahydrofuran, dioxane, dimethylformamide, dimethylsulfoxide, acetronitrile, nitromethane or hexamethylphosphoric triamide may be used.
- Goldberg et al. state that they especially prefer acetone and, in their Example 5, they dissolve N- cyclopropylmethylnoroxy-morphone in a mixture consisting of 50 ml of absolute acetone and 0.5 ml of dimethylformamide and then admix the resulting solution with methyl bromide. Methyl bromide was used in excess, greater than six-fold molar excess relative to the free base, over a period of 3 weeks in a pressure vessel.
- the present invention is a process for the preparation of a quaternary derivative of the morphinan alkaloid.
- the process comprises contacting a tertiary N-substituted morphinan alkaloid with an alkyl halide in an anhydrous solvent system, wherein the solvent system comprises an aprotic dipolar solvent with the aprotic dipolar solvent constituting at least 25 wt% of the solvent system.
- the present invention is further directed to a process for separating a liquid mixture containing a 3-alkoxymorphinan alkaloid and a 3- hydroxymorphinan alkaloid.
- the process comprises contacting the mixture with a strong base, thereby converting the 3-hydroxy morphinan alkaloid to a salt, precipitating the salt but not the 3-alkoxymorphinan alkaloid from the liquid, and separating the salt precipitate from the 3-alkoxymorphinan alkaloid.
- the product of the N- alkylation is a quaternary morphinan alkaloid derivative.
- the ternary mo ⁇ hinan alkaloid base is represented by Formula 1 and the product is represented by Formula 1A.
- A. is hydroxy, alkoxy, or acyloxy
- R 1 is hydrocarbyl or substituted hydrocarbyl
- R 2 is hydrocarbyl or substituted hydrocarbyl
- X s is an anion
- Y if present, is hydrogen, hydroxy, alkoxy, or acyloxy
- Z is hydroxy, alkoxy, or acyloxy
- the dashed lines between the carbon atoms at positions 6 and 7, 7 and 8, and 8 and 14, respectively represent (i) carbon-carbon single bonds, (ii) carbon- carbon single bonds between positions 6 and 7 and between positions 8 and 14, and a double bond between positions 7 and 8, or (iii) conjugated carbon-carbon double bonds between positions 6 and 7 and positions 8 and 14, with the proviso that Y is not present if there is a double bond between the carbons at positions 8 and 14.
- the ternary mo ⁇ hinan alkaloid base is represented by Formula 2 and the product is represented by Formula 2A.
- A. is hydroxy, alkoxy, or acyloxy
- R 1 is hydrocarbyl or substituted hydrocarbyl
- R 2 is hydrocarbyl or substituted hydrocarbyl
- X ⁇ is an anion
- Y is hydrogen, hydroxy, alkoxy, or acyloxy
- Z is hydroxy, alkoxy, or acyloxy.
- Representative ternary morphinan alkaloids falling within the scope of Formula 2 include naltrexone ((5 ⁇ )-17-(cyclopropylmethyl)-4,5-epoxy-3,14- dihydroxymorphinan-6-one), oxymorphone ((5 ⁇ )-4,5-epoxy-3,14-dihydroxy-17- methylmorphinan-6-one), oxycodone ((5 ⁇ )-4,5-epoxy-14-hydroxy-3-methoxy-17- methylmorphinan-6-one), hydromorphone ((5 ⁇ )-4,5-epoxy-3-hydroxy-17- methylmorphinan-6-one), naloxone ((5 ⁇ )-4,5-epoxy-3,14-dihydroxy-17-(2- propenyl)morphinan-6-one), nalmefene ((5 ⁇ )-17-(cyclopropylmethyl)-4,5-epoxy- 6-methylenemorphinan-3,14-diol
- R ⁇ R 2 , X s , Y and Z are as defined in connection with Formulae 2 and 2A and A 10 is oxygen, sulfur or methylene; in one embodiment, A 10 is preferably oxygen or methylene.
- Ternary morphinan alkaloids falling within the scope of Formula 2' include naltrexone, oxymo ⁇ hone, oxycodone, hydromorphone, naloxone, and nalmefene.
- Other preferred ternary morphinan alkaloids and quaternary derivatives thereof falling within the scope of Formulae 2 and 2A correspond to Formulae 2" and 2A".
- Formula 2" Formula 2A" wherein R ⁇ R 2 , X ⁇ , Y and Z are as defined in connection with Formulae 2 and 2A and A 1 is hydroxy, alkoxy or acyloxy.
- Ternary morphinan alkaloids and falling within the scope of Formulae 2" include nalbuphine.
- the ternary mo ⁇ hinan alkaloid base is represented by Formula 3 and the product is represented by Formula 3A.
- a T is hydroxy, alkoxy, or acyloxy
- R 1 is hydrocarbyl or substituted hydrocarbyl
- R 2 is hydrocarbyl or substituted hydrocarbyl
- X ⁇ is an anion
- Y is H, hydroxy, alkoxy, or acyloxy
- Z is hydroxy, alkoxy, or acyloxy.
- ternary morphinan alkaloids falling within the scope of Formula 3 include morphine ((5 ⁇ ,6 ⁇ )-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6- diol), codeine ((5 ⁇ ,6 ⁇ )-7,8-didehydro-4,5-epoxy-3-methoxy-17- methylmorphinan-6-ol), codeinone ((5 ⁇ )-7,8-didehydro-4,5-epoxy-3-methoxy-17- methylmorphinan-6-one) and 14-hydroxy-codeinone ((5 ⁇ )-7,8-didehydro-4,5- epoxy-14-hydroxy-3-methoxy-17-methyimorphinan-6-one).
- the ternary morphinan alkaloid base is represented by Formula 4 and the product is represented by Formula 4A.
- a T is hydroxy, alkoxy, or acyloxy
- R 1 is hydrocarbyl or substituted hydrocarbyl
- R 2 is hydrocarbyl or substituted hydrocarbyl
- X s is an anion
- Z is hydroxy, alkoxy, or acyloxy.
- Representative ternary morphinan alkaloids and quaternary derivatives thereof falling within the scope of Formula 4 include thebaine ((5 ⁇ )-6,7,8,14- tetradehydro-4,5-epoxy-3,6-dimethoxy-17-methylmorphinan).
- Z is preferably hydroxy, alkoxy or acyloxy, more preferably hydroxy or methoxy.
- Z may be selected from -OCH 3 , -OAc, -OTHP, -OSiR 3 (wherein each R is independently hydrocarbyl, preferably lower alkyl), -OBn, -OBz, -OBs, -OTs, or -OMs.
- Y is preferably hydrogen, hydroxy, alkoxy or acyloxy, more preferably hydrogen or hydroxy.
- Y if present, may be selected from -OCH 3 , -OAc, -OTHP, -OSiR 3 (wherein each R is independently hydrocarbyl, preferably lower alkyl), -OBn, -OBz, -OBs, -OTs, and -OMs.
- R 2 is preferably alkyl, alkenyl or alkaryl, more preferably lower alkyl, and typically methyl.
- X a is preferably a halide or an anion such as iodide, chloride, nitrate, sulfate, or phosphate for the halide anion. If X ⁇ is a halide, it is preferably bromide.
- the N-alkyl quaternary derivative of the ternary alkaloid base is prepared by contacting the base with an alkyl halide in an anhydrous solvent system. Relatively concentrated solutions are preferred.
- the reaction mixture preferably comprises no more than about 2 equivalents of solvent for each equivalent of ternary alkaloid base to solvent. In some embodiments, the reaction mixture comprises no more than about 1.75 equivalents of solvent for each equivalent of ternary alkaloid base. In other embodiments, the reaction mixture comprises no more than about 1.5 equivalents of solvent for each equivalent of ternary alkaloid base.
- a range of alkylating agents may be used in the process of the present invention. In general, alkylating agents comprising 1 to 8 carbons, optionally substituted and optionally unsaturated are preferred. Thus, for example, the alkylating agent may be a methyl, ethyl, propyl, allyl, cyclopropyl, or benzyl halide.
- the alkyl halide be an alkyl bromide. Relative to the corresponding alkyl bromides, under certain conditions alkyiations with alkyl chlorides tend to proceed slowly and alkyi iodides tend to lead to over alkylation of the ternary alkaloid substrates.
- the alkylating agent is methyl, ethyl, propyl, allyl, cyclopropyl or benzyl bromide. Preferably, it is methyl bromide.
- the solvent system for the N-alkylation comprises an aprotic, dipolar solvent and is anhydrous. That is, the solvent system comprises less than about 0.5 wt.% water, typically less than about 0.2 wt.% water, still more typically less than 0.1 wt.% water, and in some embodiments, less than 0.05 wt.% water.
- the aprotic, dipolar solvent constitute a significant fraction of the solvent system; for example, in one embodiment the aprotic, dipolar solvent constitutes at least about 25 wt% of the solvent system. In another embodiment, the aprotic, dipolar solvent constitutes at least about 50 wt% of the solvent system.
- the aprotic, dipolar solvent constitutes at least about 75 wt% of the solvent system. In a further embodiment, the aprotic, dipolar solvent constitutes at least about 90 wt% of the solvent system.
- Exemplary aprotic dipolar solvents include dimethyl acetamide, dimethyl formamide, N-methylpyrrolidinone, acetonitrile, hexamethylphosphor- amide ("HMPA”), and mixtures thereof.
- HMPA hexamethylphosphor- amide
- N-methylpyrriolidinone (1-methyl ⁇ 2- pyrrolidinone) is typically preferred, either alone or in combination with another aprotic, dipolar solvent.
- the solvent system may additionally comprise other solvents such as acetone, ether, hydrocarbon, toluene, benzene, and halobenzene.
- the reaction may be carried out over a wide range of temperatures and pressures. Surprisingly, however, it has been discovered that when methyl bromide gas is dissolved in anhydrous 1-methyl-2-pyrrolidinone, the methyl bromide is predominantly retained at temperatures of 85 °C at relatively modest elevated pressures (e.g., ⁇ 2 atmosphere, ⁇ 1.5 atmospheres, ⁇ 1.25 atmospheres) or even at atmospheric pressures without the use of relatively expensive pressure vessels. In such embodiments, the reaction will be carried out at a temperature somewhere in the range of room temperature (about 25 °C) to about 90 °C, typically about 55 to about 85 °C.
- the rate, conversion, yield and concentration of naltrexone base to the N-methylated product in anhydrous 1-methyl-2-pyrrolidinone is dramatically increased at lower reaction temperatures ( ⁇ 70 °C) as compared to the reaction in acetone carried out at 125-140 °C (> 10 atm) over 24 hours.
- the product is obtained after completion of reaction by cooling the reaction to room temperature.
- an aprotic solvent of lower polarity in which the product is not soluble is added to the reaction mixture to increase "flowability" and to enhance precipitation ⁇ .
- the resulting mixture is preferably stirred, vacuum filtered and dried to yield a crude product.
- the aprotic solvent of low polarity used is selected from acetone, ether, or hydrocarbon such as benzene or toluene.
- N-alkylations of morphinan substrates that contain a 3-hydroxy moiety may yield undesirable 3- alkoxymorphinans.
- Crude product mixtures containing 3-hydroxy and 3- alkoxymorphinans may be purified by adding strong base, e.g., sodium methoxide, NaOH, or KOH in methanol/water, heating the mixture to convert the 3-hydroxymorphinan to its salt (e.g., sodium salt), adding additional methanol, cooling to precipitate the salt, filtering and drying.
- the 3- alkoxymorphinan remains in solution and does not precipitate along with the salt; as a result, the salt and the 3-alkoxymorphinan may be readily separated.
- the desired N-alkyl mo ⁇ hinan may be regenerated from the salt by redissolving the salt (for example, in a methanol/water solution), adjusting the solution to a low pH (for example, a pH of 0.5 to 1 using 45% hydrobromic acid) to regenerate a hydroxy group at the 3-position, and precipitating the product.
- the precipitated product is recovered by vacuum filtration, washing with additional methanol and drying to 75°C.
- the alkylating agent is an alkyl halide
- the N-alkyl morphinan alkaloid will contain a halide anion.
- This anion may be exchanged at various stages in the process by treating the N-alkyl morphinan alkaloid with a protic acid, thereby exchanging an anion such as iodide, chloride, nitrate, sulfate, or phosphate for the halide anion.
- an anion such as iodide, chloride, nitrate, sulfate, or phosphate for the halide anion.
- Ts means tosyl
- anhydrous solvent refers to solvents containing less than 0.5% by weight water, preferably maintained and handled under nitrogen gas during a reaction.
- hydrocarbon and “hydrocarbyl” as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties.
- moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to
- substituted hydrocarbyl moieties described herein are hydrocarbyl moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom.
- substituents include halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryioxy, hydroxy, keto, acyl, acyloxy, nitro, tertiaryamino, amido, nitro, cyano, ketals, acetals, esters and ethers.
- alkyl groups described herein are preferably lower alkyl containing from one to eight carbon atoms in the principal chain. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, allyl, benzyl, hexyl and the like.
- alkenyl groups described herein are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.
- alkynyl groups described herein are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.
- acyl denotes the moiety formed by removal of the hydroxyl group from the group -COOH of an organic carboxylic acid, e.g., RC(O)-, wherein R is R 1 , R 1 0-, R 1 R 2 N-, or R 1 S-, R 1 is hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo, and R 2 is hydrogen, hydrocarbyl or substituted hydrocarbyl.
- acyloxy denotes an acyl group as described above bonded through an oxygen linkage (--0-), e.g., RC(0)O- wherein R is as defined in connection with the term "acyl.”
- aryl or “ar” as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyi are the more preferred aryl.
- halogen or “halo” as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.
- halide refers to fluoride, chloride, bromide, or iodide ions.
- narcotics refers to drugs that depress the central nervous system and relieve pain when used in moderate doses.
- opioid refers to non-opium-derived (synthetic or naturally occuring)narcotics that act on the central nervous system to decrease the sensation of pain.
- a 3-necked 500-mL flask was fitted with an addition funnel, thermocouple, condenser and a mechanical stirrer.
- 100 ml_ of 1-methyl-2- pyrrolidinone was added to the flask under a sweep of dry nitrogen and was heated to 55°C.
- the addition funnel was replaced with a powder funnel, 100 gm of naltrexone anhydrous base was added with stirring, the funnel was "washed down" with 25 mL of 1-methyl-2-pyrrolidinone and the temperature was adjusted to 55-58°C.
- the addition funnel was placed back on the 3-necked flask. Separately, 25 mL of anhydrous 1-methyl-2-pyrrolidinone was cooled in a graduated cylinder.
- Methyl bromide gas was condensed in a lecture bottle using an ice bath and 25 mL was measured out as a liquid into another cold graduated cylinder. The cold methyl bromide liquid and 1-methyl-2-pyrrolidinone were combined and mixed. The methyl bromide solution was poured into the addition funnel and then added dropwise to the naltrexone base under a slow sweep of dry nitrogen. The reaction temperature was increased to 61-65°C. A mild exotherm was noted.
- the undesirable phenolic (O-alkyl) side-products were removed by first converting the O-alkyl impurity in crude N-naltrexone methyl bromide into its sodium alkoxide salt utilizing a strong base, e.g., 40 mL of 25% sodium methoxide in methanol/water (220 mL/120 mL). The solution was heated to 50- 65°C with an additional 500 mL of methanol. The solution was cooled to 20- 25°C for 60-90 min. The sodium salt crystallized on stirring and was recovered by vacuum filtration. After drying at 60°C under nitrogen, the sodium salt weighed 53-55 g.
- a strong base e.g. 40 mL of 25% sodium methoxide in methanol/water (220 mL/120 mL.
- the solution was heated to 50- 65°C with an additional 500 mL of methanol.
- the solution was cooled to 20- 25°C for 60-90 min.
- the product was regenerated by adjusting the pH of a methanol/water (100 mL, ratio 5:7.5) sodium salt solution to 0.5-1 with 25 g of 45% hydrobromic acid.
- the solution was filtered, 150 mL of methanol added, the temperature was adjusted to 50-55°C and finally cooled to ice-bath temperature.
- the white precipitated product was recovered by vacuum filtration and washed with 75 mL of methanol. After drying to 75°C, the purified product weighed -45 g.
- the product was 99.5% pure by HPLC assessment relative to an analytical standard. The procedure described above is applicable to other N-alkylations.
- Naltrexone base (40.0 grams) was dissolved in N,N-dimethylformamide (DMF) (50 mL Mallinckrodt, AR) with mild heating and then purged with dry house nitrogen.
- Methyl bromide (5 mL, Aldrich) cooled to ice bath temperature was measured out into a cold ( ⁇ 5 °C) 10 mL graduated cylinder and quickly added to the reaction flask. With the bubbler left in place, the glass flask was heated to 65 °C for ten hours. The crude product was recovered from the DMF by precipitation with acetone (75 mL, Mallinckrodt AR) after a short reflux period.
- Methyl bromide gas was condensed in a lecture bottle using an ice bath and 10 mL was measured out as a liquid into another cold graduated cylinder.
- the cold methyl bromide liquid and 1-methyl-2-pyrrolidinone were combined and mixed.
- the methyl bromide solution was poured into the addition funnel and then added dropwise to the naltrexone base under a slow sweep of dry nitrogen. An exotherm was noted and the temperature of the solution climbed to 66 °C.
- the reaction temperature and time was set at 62.5 °C for nine hours. After an hour, a fine white suspension of naltrexone methobromide began to form. At the end of nine hours the heating was discontinued and the mixture was allowed to cool to room temperature and left stirring overnight.
- Acetone 75 mL was poured into the suspension to facilitate the precipitation of soluble product.
- the slurry was cooled to ice bath temperature and stirred.
- the product was recovered by vacuum filtration and washed with 25 mL of additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 °C.
- the yield of the unpurified product was 31.8 g .
- Methyl bromide gas was condensed in a lecture bottle using an ice bath and 8 mL was measured out as a liquid into another cold graduated cylinder.
- the cold methyl bromide liquid and 1-methyl-2-pyrrolidinone were combined and mixed.
- the methyl bromide solution was poured into the addition funnel and then added dropwise to the naltrexone base under a slow sweep of dry nitrogen.
- the reaction temperature was increased to a set temperature of 62.5 °C for nine hours. After about two hours, a fine white suspension of naltrexone methobromide began to form. At the end of nine hours the heating was discontinued and the mixture was allowed to cool to room temperature and left stirring overnight.
- Acetone 75 mL was poured into the suspension to facilitate the precipitation of soluble product.
- the slurry was cooled to ice bath temperature and stirred.
- the product was recovered by vacuum filtration and washed with 25 mL of additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 °C.
- the yield of the unpurified product was 26.9 g .
- Methyl bromide gas was condensed in a lecture bottle using an ice bath and 0.5 mL was measured out as a liquid into another cold graduated cylinder.
- the methyl bromide was poured into the naltrexone base suspension under a slow sweep of dry nitrogen.
- the reaction temperature and time was set at 72.5 °C for six hours. At the end of six hours, the heating was discontinued and the mixture was allowed to cool to room temperature and left stirring overnight.
- Acetone (15 mL) was poured into the suspension to facilitate the precipitation of soluble product.
- the slurry was cooled to ice bath temperature and stirred.
- the product was recovered by vacuum filtration and washed with additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 °C.
- the yield of the unpurified product was 1.77 g .
- Acetone (15 mL) was poured into the suspension to facilitate the precipitation of soluble product.
- the slurry was cooled to ice bath temperature and stirred.
- the product was recovered by vacuum filtration and washed with additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 G C.
- the yield of the unpurified product was 1.87 g .
- Methyl bromide gas was condensed in a lecture bottle using an ice bath and 1 mL was measured out as a liquid into another cold graduated cylinder.
- the methyl bromide was poured into the naltrexone base suspension under a slow sweep of dry nitrogen.
- the reaction temperature and time was set at 65 °C for eight hours. A white suspension began to form after one hour. At the end of eight hours, the heating was discontinued and the mixture was allowed to cool to room temperature and left stirring overnight.
- Acetone (15 mL) was poured into the suspension to facilitate the precipitation of soluble product. The slurry was cooled to ice bath temperature and stirred. The product was recovered by vacuum filtration and washed with additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 °C.
- the yield of the unpurified product was 3.9 g's at a 93.5 % purity by area on HPLC analysis. 3.68 Grams of white salt was obtained after recrystallization from methanol/water and drying.
- Acetone (15 mL) was poured into the suspension to facilitate the precipitation of soluble product.
- the slurry was cooled to ice bath temperature and stirred.
- the product was recovered by vacuum filtration and washed with additional acetone.
- the product was dried to a constant weight in a vacuum oven set at 60 °C.
- the yield of the unpurified product was 1.63 g .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004551830A JP2006509745A (en) | 2002-11-08 | 2003-11-05 | Method for producing quaternary N-alkyl morphinan alkaloid salt |
MXPA05004759A MXPA05004759A (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts. |
AT03783211T ATE444295T1 (en) | 2002-11-08 | 2003-11-05 | METHOD FOR PRODUCING QUATERNARY N-ALKYL MORPHINANE ALKALOID SALTS |
EP03783211A EP1562953B1 (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
DE60329520T DE60329520D1 (en) | 2002-11-08 | 2003-11-05 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS |
US10/530,446 US7285665B2 (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
CA2504262A CA2504262C (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
AU2003290630A AU2003290630B2 (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42474802P | 2002-11-08 | 2002-11-08 | |
US60/424,748 | 2002-11-08 | ||
US42558002P | 2002-11-12 | 2002-11-12 | |
US60/425,580 | 2002-11-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004043964A2 true WO2004043964A2 (en) | 2004-05-27 |
WO2004043964A3 WO2004043964A3 (en) | 2004-08-26 |
Family
ID=32314554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/035463 WO2004043964A2 (en) | 2002-11-08 | 2003-11-05 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
Country Status (11)
Country | Link |
---|---|
US (1) | US7285665B2 (en) |
EP (1) | EP1562953B1 (en) |
JP (1) | JP2006509745A (en) |
AT (1) | ATE444295T1 (en) |
AU (1) | AU2003290630B2 (en) |
CA (1) | CA2504262C (en) |
DE (1) | DE60329520D1 (en) |
ES (1) | ES2332453T3 (en) |
MX (1) | MXPA05004759A (en) |
PT (1) | PT1562953E (en) |
WO (1) | WO2004043964A2 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006127898A2 (en) * | 2005-05-25 | 2006-11-30 | Progenics Pharmaceuticals, Inc. | (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use |
WO2006127899A2 (en) | 2005-05-25 | 2006-11-30 | Progenics Pharmaceuticals, Inc. | (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
WO2008016704A1 (en) * | 2006-08-04 | 2008-02-07 | Wyeth | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
WO2008034973A1 (en) * | 2006-09-21 | 2008-03-27 | Sanofi-Aventis | Process for preparing n-alkyl naltrexone halides |
WO2008064150A1 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers |
WO2008064353A2 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
WO2008109156A2 (en) | 2007-03-06 | 2008-09-12 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
WO2008121352A2 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
WO2008138383A1 (en) * | 2007-05-16 | 2008-11-20 | Cilag Ag | Method for the production of n-methyl naltrexone bromide |
WO2009009292A2 (en) * | 2007-07-11 | 2009-01-15 | Mallinckrodt Inc. | Crystalline forms of naltrexone methobromide |
EP2019105A1 (en) * | 2007-07-19 | 2009-01-28 | Siegfried Ltd. | Process for the preparation of quaternary n-alkyl morphine or morphinane alkaloid derivatives |
WO2010121369A1 (en) | 2009-04-24 | 2010-10-28 | Brock University | Processes for the preparation of morphinane and morphinone compounds |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US8115002B2 (en) | 2006-09-20 | 2012-02-14 | Mallinckrodt Llc | Preparation of substituted morphinan-6-ones and salts and intermediates thereof |
US8148528B2 (en) | 2008-05-27 | 2012-04-03 | Mallinckrodt Llc | Processes and compounds for the preparation of normorphinans |
US8247425B2 (en) | 2008-09-30 | 2012-08-21 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8338446B2 (en) | 2007-03-29 | 2012-12-25 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8471022B2 (en) | 2008-02-06 | 2013-06-25 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US8546418B2 (en) | 2007-03-29 | 2013-10-01 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
US8552025B2 (en) | 2003-04-08 | 2013-10-08 | Progenics Pharmaceuticals, Inc. | Stable methylnaltrexone preparation |
US8563727B2 (en) | 2009-02-23 | 2013-10-22 | Mallinckrodt Llc | (+)-morphinanium N-oxides and processes for their production |
US8563721B2 (en) | 2008-06-20 | 2013-10-22 | Chongqing Pharmaceutical Research Institute Co., Ltd. | Morphinan derivatives and preparation methods thereof |
US8563724B2 (en) | 2009-02-23 | 2013-10-22 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US8624031B2 (en) | 2011-09-08 | 2014-01-07 | Mallinckrodt Llc | Production of alkaloids without the isolation of intermediates |
AU2013200437B2 (en) * | 2005-05-25 | 2015-01-15 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone, process for its synthesis and its pharmaceutical use |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US9040726B2 (en) | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
US9458109B2 (en) | 2008-09-03 | 2016-10-04 | Mallinckrodt Llc | Substituted berbines and processes for their synthesis |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9675602B2 (en) | 2005-03-07 | 2017-06-13 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9717725B2 (en) | 2005-03-07 | 2017-08-01 | The University Of Chicago | Use of opioid antagonists |
US10383869B2 (en) | 2008-03-21 | 2019-08-20 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009023567A1 (en) * | 2007-08-09 | 2009-02-19 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
US20110112129A2 (en) * | 2007-11-26 | 2011-05-12 | Pharmacofore, Inc. | Peripheral Phenolic Opioid Antagonist |
TR201809734T4 (en) * | 2008-02-14 | 2018-07-23 | Alkermes Inc | Selective opioid compounds. |
WO2011154826A1 (en) | 2010-06-11 | 2011-12-15 | Rhodes Technologies | Process for n-dealkylation of tertiary amines |
AU2011263417B2 (en) | 2010-06-11 | 2014-03-27 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof |
ES2784690T3 (en) | 2013-12-05 | 2020-09-29 | Univ Bath | New opioid compounds and their uses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
WO2004005294A2 (en) * | 2002-07-03 | 2004-01-15 | Alcasynn Pharmaceuticals Gmbh | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3101339A (en) * | 1958-10-30 | 1963-08-20 | Boehringer Sohn Ingelheim | Quaternary salts of normorphine and its acylated derivatives |
US4141897A (en) * | 1976-12-20 | 1979-02-27 | Research Corporation | N-dealkylation of N-alkyl-14-hydroxymorphinans and derivatives thereof |
PL124001B1 (en) | 1980-01-25 | 1982-12-31 | Inst Przemyslu Zielarskiego | Process for preparing quaternary halides of n-alkylor n-aralkyl- derivatives of tropanic and isoquinolylic alkaloids |
US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
US5668285A (en) * | 1986-10-31 | 1997-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates |
DE4132159A1 (en) * | 1991-09-27 | 1993-04-01 | Boehringer Ingelheim Kg | 14-HYDROXY-N- (2-METHOXYETHYL) -7,8-DIHYDROMORPHINE AND -NORISOMORPHINE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUG |
US5574159A (en) * | 1992-02-03 | 1996-11-12 | Delta Pharmaceuticals, Inc. | Opioid compounds and methods for making therefor |
US5352680A (en) * | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
SE9401728D0 (en) | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds II |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
US5756851A (en) * | 1996-10-21 | 1998-05-26 | Albemarle Corporation | Production of nabumetone or precursors thereof |
GB9713703D0 (en) * | 1997-06-30 | 1997-09-03 | Johnson Matthey Plc | Preparation of opiates |
WO2001014382A1 (en) * | 1999-08-23 | 2001-03-01 | Toray Industries, Inc. | Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan |
-
2003
- 2003-11-05 DE DE60329520T patent/DE60329520D1/en not_active Expired - Lifetime
- 2003-11-05 JP JP2004551830A patent/JP2006509745A/en active Pending
- 2003-11-05 AT AT03783211T patent/ATE444295T1/en active
- 2003-11-05 CA CA2504262A patent/CA2504262C/en not_active Expired - Lifetime
- 2003-11-05 EP EP03783211A patent/EP1562953B1/en not_active Expired - Lifetime
- 2003-11-05 ES ES03783211T patent/ES2332453T3/en not_active Expired - Lifetime
- 2003-11-05 AU AU2003290630A patent/AU2003290630B2/en not_active Expired
- 2003-11-05 WO PCT/US2003/035463 patent/WO2004043964A2/en active Application Filing
- 2003-11-05 MX MXPA05004759A patent/MXPA05004759A/en active IP Right Grant
- 2003-11-05 PT PT03783211T patent/PT1562953E/en unknown
- 2003-11-05 US US10/530,446 patent/US7285665B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
WO2004005294A2 (en) * | 2002-07-03 | 2004-01-15 | Alcasynn Pharmaceuticals Gmbh | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof |
Cited By (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US8552025B2 (en) | 2003-04-08 | 2013-10-08 | Progenics Pharmaceuticals, Inc. | Stable methylnaltrexone preparation |
US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9675602B2 (en) | 2005-03-07 | 2017-06-13 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9717725B2 (en) | 2005-03-07 | 2017-08-01 | The University Of Chicago | Use of opioid antagonists |
EP2450359A3 (en) * | 2005-05-25 | 2012-08-22 | Progenics Pharmaceuticals, Inc. | (R)-N-Methylnaltrexone |
JP2015129190A (en) * | 2005-05-25 | 2015-07-16 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
JP2013075905A (en) * | 2005-05-25 | 2013-04-25 | Progenics Pharmaceuticals Inc | (r)-n-methylnaltrexone, synthetic method and medical use of the same |
TWI383984B (en) * | 2005-05-25 | 2013-02-01 | Progenics Pharm Inc | Synthesis of (r)-n-methylnaltrexone |
US8343992B2 (en) | 2005-05-25 | 2013-01-01 | Progenics Pharmaceuticals, Inc. | Synthesis of R-N-methylnaltrexone |
EP3219717A1 (en) | 2005-05-25 | 2017-09-20 | Progenics Pharmaceuticals, Inc. | Pharmaceutical compositions comprising (r)-n-methylnaltrexone |
JP2017137346A (en) * | 2005-05-25 | 2017-08-10 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
JP2008542286A (en) * | 2005-05-25 | 2008-11-27 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | (S) -N-methylnaltrexone, synthesis method thereof and pharmaceutical use thereof |
WO2006127898A2 (en) * | 2005-05-25 | 2006-11-30 | Progenics Pharmaceuticals, Inc. | (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use |
US8916581B2 (en) | 2005-05-25 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
EP2450360A3 (en) * | 2005-05-25 | 2012-08-22 | Progenics Pharmaceuticals, Inc. | (S)-N-Methylnaltrexone |
WO2006127899A2 (en) | 2005-05-25 | 2006-11-30 | Progenics Pharmaceuticals, Inc. | (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
AU2013200437B2 (en) * | 2005-05-25 | 2015-01-15 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone, process for its synthesis and its pharmaceutical use |
WO2006127898A3 (en) * | 2005-05-25 | 2007-02-08 | Progenics Pharm Inc | (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use |
WO2006127899A3 (en) * | 2005-05-25 | 2007-02-08 | Progenics Pharm Inc | (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
US9597327B2 (en) | 2005-05-25 | 2017-03-21 | Progenics Pharmaceuticals, Inc. | Synthesis of (R)-N-methylnaltrexone |
EP2450359A2 (en) | 2005-05-25 | 2012-05-09 | Progenics Pharmaceuticals, Inc. | (R)-N-Methylnaltrexone |
EP2450360A2 (en) | 2005-05-25 | 2012-05-09 | Progenics Pharmaceuticals, Inc. | (S)-N-Methylnaltrexone |
TWI478927B (en) * | 2005-05-25 | 2015-04-01 | Progenics Pharm Inc | (s)-n-methylnaltrexone |
US7674904B2 (en) | 2005-05-25 | 2010-03-09 | Progenics Pharmaceuticals, Inc. | Synthesis of R-N-methylnaltrexone |
US8003794B2 (en) | 2005-05-25 | 2011-08-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
US7501434B2 (en) | 2006-08-04 | 2009-03-10 | Wyeth | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
JP2009545629A (en) * | 2006-08-04 | 2009-12-24 | ワイス | 6-Carboxynormorphinan derivatives, their synthesis and use |
WO2008016704A1 (en) * | 2006-08-04 | 2008-02-07 | Wyeth | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
US8115002B2 (en) | 2006-09-20 | 2012-02-14 | Mallinckrodt Llc | Preparation of substituted morphinan-6-ones and salts and intermediates thereof |
AU2007298855B2 (en) * | 2006-09-21 | 2012-09-13 | Sanofi-Aventis | Process for preparing N-alkyl naltrexone halides |
KR101434693B1 (en) * | 2006-09-21 | 2014-08-27 | 사노피 | Process for preparing n-alkyl naltrexone halides |
EA015426B1 (en) * | 2006-09-21 | 2011-08-30 | Санофи-Авентис | Process for preparing n-alkylnaltrexone halides |
CN102225939A (en) * | 2006-09-21 | 2011-10-26 | 赛诺菲-安万特 | Process for preparing N-alkylnaltrexone halides |
TWI465451B (en) * | 2006-09-21 | 2014-12-21 | Sanofi Aventis | Process for preparing n-alkylnaltrexone halides |
US8288547B2 (en) | 2006-09-21 | 2012-10-16 | Sanofi | N-methylnaltrexone zwitterion |
US7645880B2 (en) | 2006-09-21 | 2010-01-12 | Sanofi-Aventis | Processs for preparing N-alkylnaltrexone halides |
FR2906252A1 (en) * | 2006-09-21 | 2008-03-28 | Sanofi Aventis Sa | PROCESS FOR THE PREPARATION OF NALTREXONE N-AKLYL HALIDES |
WO2008034973A1 (en) * | 2006-09-21 | 2008-03-27 | Sanofi-Aventis | Process for preparing n-alkyl naltrexone halides |
WO2008064150A1 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers |
WO2008064353A3 (en) * | 2006-11-22 | 2008-11-27 | Progenics Pharm Inc | 7,8-saturated-4,5-epoxy-morphinanium analogs |
WO2008064353A2 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
EP2147920A2 (en) | 2007-03-06 | 2010-01-27 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
AU2008223328B2 (en) * | 2007-03-06 | 2012-10-11 | SpecGx LLC | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
AU2009227892B2 (en) * | 2007-03-06 | 2012-09-27 | SpecGx LLC | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
WO2008109156A3 (en) * | 2007-03-06 | 2008-11-20 | Mallinckrodt Inc | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
US9415044B2 (en) | 2007-03-06 | 2016-08-16 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
US9040726B2 (en) | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
EP2147920A3 (en) * | 2007-03-06 | 2010-03-24 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
WO2008109156A2 (en) | 2007-03-06 | 2008-09-12 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
US8669366B2 (en) | 2007-03-06 | 2014-03-11 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
US8338446B2 (en) | 2007-03-29 | 2012-12-25 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
WO2008121352A3 (en) * | 2007-03-29 | 2009-01-15 | Progenics Pharm Inc | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
EP3263571B1 (en) | 2007-03-29 | 2019-11-13 | Progenics Pharmaceuticals, Inc. | Crystal form of (r)-n-methylnaltrexone bromide and uses thereof |
WO2008121352A2 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
US9879024B2 (en) | 2007-03-29 | 2018-01-30 | Progenics Pharmaceuticals., Inc. | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
EP3263571A1 (en) * | 2007-03-29 | 2018-01-03 | Progenics Pharmaceuticals, Inc. | Crystal form of (r)-n-methylnaltrexone bromide and uses thereof |
US8546418B2 (en) | 2007-03-29 | 2013-10-01 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
US9102680B2 (en) | 2007-03-29 | 2015-08-11 | Wyeth Llc | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
US8853232B2 (en) | 2007-03-29 | 2014-10-07 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8772310B2 (en) | 2007-03-29 | 2014-07-08 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8318936B2 (en) | 2007-05-16 | 2012-11-27 | Cilag Ag | Method for producing N-methylnaltrexone bromide |
WO2008138383A1 (en) * | 2007-05-16 | 2008-11-20 | Cilag Ag | Method for the production of n-methyl naltrexone bromide |
WO2008138605A3 (en) * | 2007-05-16 | 2009-04-30 | Cilag Ag | Method for producing n-methylnaltrexone bromide |
WO2008138605A2 (en) * | 2007-05-16 | 2008-11-20 | Cilag Ag | Method for producing n-methylnaltrexone bromide |
WO2009009292A2 (en) * | 2007-07-11 | 2009-01-15 | Mallinckrodt Inc. | Crystalline forms of naltrexone methobromide |
US8383649B2 (en) | 2007-07-11 | 2013-02-26 | Mallinckrodt Llc | Crystalline forms of naltrexone methobromide |
WO2009009292A3 (en) * | 2007-07-11 | 2009-04-30 | Mallinckrodt Inc | Crystalline forms of naltrexone methobromide |
EP2019105A1 (en) * | 2007-07-19 | 2009-01-28 | Siegfried Ltd. | Process for the preparation of quaternary n-alkyl morphine or morphinane alkaloid derivatives |
US8101756B2 (en) | 2007-07-19 | 2012-01-24 | Siegfried Ltd. | Process for the preparation of quaternary N-alkyl morphin or morphinan alkaloid derivatives |
EP2039696A1 (en) | 2007-07-19 | 2009-03-25 | Siegfried Ltd. | Process for the preparation of quaternary N-alkyl morphine or morphinane alkaloid derivatives |
EP2730578A1 (en) | 2008-02-06 | 2014-05-14 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnal trexone |
US8471022B2 (en) | 2008-02-06 | 2013-06-25 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US8916706B2 (en) | 2008-02-06 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US10383869B2 (en) | 2008-03-21 | 2019-08-20 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
US8148528B2 (en) | 2008-05-27 | 2012-04-03 | Mallinckrodt Llc | Processes and compounds for the preparation of normorphinans |
US8563721B2 (en) | 2008-06-20 | 2013-10-22 | Chongqing Pharmaceutical Research Institute Co., Ltd. | Morphinan derivatives and preparation methods thereof |
US9458109B2 (en) | 2008-09-03 | 2016-10-04 | Mallinckrodt Llc | Substituted berbines and processes for their synthesis |
US9856251B2 (en) | 2008-09-03 | 2018-01-02 | Mallinckrodt Llc | Substituted berbines and processes for their synthesis |
US8247425B2 (en) | 2008-09-30 | 2012-08-21 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US9492445B2 (en) | 2008-09-30 | 2016-11-15 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US8455644B2 (en) | 2008-09-30 | 2013-06-04 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US9724343B2 (en) | 2008-09-30 | 2017-08-08 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US8420663B2 (en) | 2008-09-30 | 2013-04-16 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8822490B2 (en) | 2008-09-30 | 2014-09-02 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US8563724B2 (en) | 2009-02-23 | 2013-10-22 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US8563727B2 (en) | 2009-02-23 | 2013-10-22 | Mallinckrodt Llc | (+)-morphinanium N-oxides and processes for their production |
WO2010121369A1 (en) | 2009-04-24 | 2010-10-28 | Brock University | Processes for the preparation of morphinane and morphinone compounds |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US8624031B2 (en) | 2011-09-08 | 2014-01-07 | Mallinckrodt Llc | Production of alkaloids without the isolation of intermediates |
Also Published As
Publication number | Publication date |
---|---|
EP1562953B1 (en) | 2009-09-30 |
AU2003290630A1 (en) | 2004-06-03 |
CA2504262C (en) | 2012-01-10 |
MXPA05004759A (en) | 2005-08-02 |
AU2003290630B2 (en) | 2009-01-29 |
WO2004043964A3 (en) | 2004-08-26 |
JP2006509745A (en) | 2006-03-23 |
CA2504262A1 (en) | 2004-05-27 |
PT1562953E (en) | 2009-11-19 |
EP1562953A2 (en) | 2005-08-17 |
US7285665B2 (en) | 2007-10-23 |
DE60329520D1 (en) | 2009-11-12 |
US20060014771A1 (en) | 2006-01-19 |
ES2332453T3 (en) | 2010-02-05 |
ATE444295T1 (en) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562953B1 (en) | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | |
US8669366B2 (en) | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | |
EP1994034B1 (en) | Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds | |
US9415044B2 (en) | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | |
JP2010520288A5 (en) | ||
EP2344507B1 (en) | Processes for increasing the yield of the hydrolysis of the 3-o-methyl and 17-n-nitrile group in the preparation of opiate alkaloid derivatives | |
US20110269964A1 (en) | N-Alkylation of Opiates | |
EP2039696B1 (en) | Process for the preparation of quaternary N-alkyl morphine or morphinane alkaloid derivatives | |
CN100379741C (en) | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2006014771 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10530446 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004551830 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2504262 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/004759 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 831/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A2817X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003290630 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003783211 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003783211 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10530446 Country of ref document: US |